A

Allogene Therapeutics
D

ALLO

1.87500
USD
-0.15
(-7.41%)
Post Trading·1.89000USD+0.01500(+0.80%)
حجم التداول
193,332
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
647,164,802
المقالات
المزيد

العنوان: Allogene Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).